Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in plati

Trial Details

NCT ID
NCT04518501
Phase
PHASE1 / PHASE2
Sponsor
Xing Xie
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Arsenic trioxide Tablet +Fuzuloparib Capsules
Locations (sample)
  • Zhejiang, Hangzhou, China|25.3238,105.583

Key Eligibility Criteria

  • 18-70years old;
  • High grade (serous or endometrioid) epithelial ovarian cancers, fallopian tube or primary peritoneal carcinoma;
  • Patients received at least two lines of platinum-containing chemotherapy, with recurrence occurring within six months after the last chemotherapy d…
  • Measurable disease as per RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →